Claritev Corporation (NYSE: CTEV) files a range of documents with the U.S. Securities and Exchange Commission that detail its operations as a healthcare technology, data and insights company. As an issuer of Class A common stock listed on the New York Stock Exchange, Claritev provides investors with periodic and current reports that describe its financial performance, capital structure, client relationships and key corporate events.
On this page, you can access Claritev’s SEC filings, including current reports on Form 8-K that the company uses to announce material developments. Recent 8-K filings have covered topics such as quarterly financial results, contract renewals with its ten largest clients, underwriting agreements for secondary offerings of Class A common stock by selling stockholders, and changes in executive roles. These filings also confirm that Claritev’s Class A common stock, with a par value of $0.0001 per share, is registered under Section 12(b) and trades under the symbol CTEV on the NYSE.
Claritev’s earnings-related filings and exhibits provide detail on revenues, net income or loss, and non-GAAP metrics such as EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and an Adjusted cash conversion ratio. The company defines these measures and explains their limitations, giving investors insight into how management evaluates performance and cash generation alongside GAAP results.
Through Stock Titan, these filings are complemented by AI-powered summaries that help explain the significance of each document. Investors can quickly see the key points from Claritev’s 8-Ks, and, where available, review annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy materials and other disclosures. This page also provides a pathway to monitor any insider-related filings, such as Form 4 reports, that may be associated with Claritev’s equity compensation and ownership changes, offering a structured view of the company’s regulatory reporting history.
Claritev Corporation reported mixed first-quarter 2026 results with modest growth but continued losses and heavy leverage. Revenues reached $244.7 million, up 5.8% from $231.3 million a year earlier, while Adjusted EBITDA rose 3.4% to $146.9 million, implying a 60.0% margin versus 61.4% in 2025.
The company posted a net loss of $73.6 million, slightly larger than the $71.3 million loss a year earlier, and net loss per share was $4.41. Operating cash flow was negative at $45.8 million and Free Cash Flow was a negative $92.5 million, reflecting high capital expenditures and interest costs.
Claritev ended the quarter with $21.3 million of unrestricted cash and total assets of about $4.84 billion against total liabilities of about $5.07 billion, resulting in a shareholders’ deficit. Management nudged full-year 2026 revenue guidance up to a range of $985 million to $1.0 billion, while keeping Adjusted EBITDA, capital expenditure, tax rate, and Free Cash Flow guidance unchanged.
Klapstein Julie D reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Julie D. Klapstein received a grant of 8,977 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost per share and increases her direct holdings to 24,611 shares.
The restricted stock units vest on the earlier of one year from the grant date or the next regularly scheduled annual stockholder meeting, provided she continues serving through that date. If she resigns voluntarily without cause before then, the units vest on a pro rata basis according to days of service.
Klein Michael Stuart reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Michael Stuart Klein reported an equity award and updated share holdings. He received 8,977 shares of Class A common stock as restricted stock units at $0.00 per share, bringing his direct holdings to 24,334 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual stockholder meeting, subject to continued service, with pro rata vesting in certain voluntary resignation scenarios. The filing also reports 195,490 Class A shares held indirectly by M. Klein Associates, Inc. and another entity for which he serves as managing member. Klein is the controlling stockholder of M. Klein Associates, Inc. and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Clarke Richard A reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Clarke Richard A reported receiving a grant of 8,977 shares of Class A common stock in the form of restricted stock units at a price of $0.00 per share. Following this equity award, he directly holds 24,334 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the issuer’s next regularly scheduled annual stockholder meeting, subject to continued service. If he voluntarily resigns when there are no grounds for termination for cause, the units vest on a pro rata basis according to days of service.
Kap Jason Lamar reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Jason Lamar Kap received an award of 8,977 shares of Class A common stock as restricted stock units. These units vest on the earlier of one year from the grant date or the next annual stockholder meeting, subject to continued service.
Following this grant, he directly holds 16,333 shares. If he voluntarily resigns (other than for cause), the restricted stock units vest on a pro rata basis according to days of service provided before departure.
HARRIS C MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Harris C. Martin received an equity award of 8,977 shares of Class A common stock in the form of restricted stock units. The award was granted at a price of $0.00 per share as compensation, not through an open-market purchase.
After this grant, Martin directly holds 24,282 shares of Claritev Corp common stock. The restricted stock units vest on the earlier of one year from the grant date or the next regularly scheduled annual stockholder meeting, subject to continued service, with pro rata vesting in certain resignation scenarios.
Prince John Michael reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Prince John Michael received an equity grant of Class A common stock. On April 29, 2026, he was awarded 8,977 restricted stock units at a stated price of $0.00 per share, increasing his directly held position to 21,662 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, subject to continued service. If he voluntarily resigns (other than for cause), the units vest pro rata based on days of service.
Colaluca Anthony Jr reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Anthony Jr. Colaluca received a grant of 8,977 shares of Class A common stock as restricted stock units. The award was made at a price of $0.00 per share, increasing his directly held Class A common stock to 24,334 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, subject to continued service. If he voluntarily resigns (without grounds for termination for cause), the units vest on a pro rata basis based on days of service. He also indirectly holds 5,500 shares through a trust.
Claritev Corporation held its Annual Meeting on April 29, 2026, where stockholders approved an amendment to the 2020 Omnibus Incentive Plan that increases the common stock reserved under the plan by an additional 2,375,000 shares. Stockholders also elected four Class III directors to the Board and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. In advisory voting, stockholders approved the compensation of the named executive officers and supported the incentive plan amendment, indicating broad backing for the company’s current governance and compensation structure.